Key facts
- It has raised $32.7M; the latest was Early Stage VC ($32.7M) in Mar 2026.
- Notable investors include Takeda Ventures, Byers Capital Investment Advisory, Neuro.Vc.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Oryon Cell Therapies
- ·The full record, as it builds
Funding rounds
No funding rounds for Oryon Cell Therapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oryon Cell Therapies
Operator of a biopharmaceutical company intended to treat brain diseases. The company uses autologous cell therapy for the development of regenerative medicine to fundamentally restore normal motor function, enabling patients to recover from Parkinson's disease.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2020
- Website
- oryoncelltherapies.com/
- Ownership
- Privately Held (backing)
Oryon Cell Therapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oryon Cell Therapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oryon Cell Therapies in its N-PORT filings yet. We sweep new filings monthly.